Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations.

Front Immunol · 2023 · PMC10478078 · PMID 37675113

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significancep-value = 0.076so close (0.05 < p ≤ 0.1)

Persistent and transient antibodies were found more frequently in patients with IRE compared to patients with DE, although it did not reach statistical significance (p-value = 0.076; p-value=0.051). 3.4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.